ATE185901T1 - Quantitativer gerinnungstest für aktivierten faktor vii - Google Patents

Quantitativer gerinnungstest für aktivierten faktor vii

Info

Publication number
ATE185901T1
ATE185901T1 AT92917364T AT92917364T ATE185901T1 AT E185901 T1 ATE185901 T1 AT E185901T1 AT 92917364 T AT92917364 T AT 92917364T AT 92917364 T AT92917364 T AT 92917364T AT E185901 T1 ATE185901 T1 AT E185901T1
Authority
AT
Austria
Prior art keywords
factor
assay
viia
factor viia
factor vii
Prior art date
Application number
AT92917364T
Other languages
English (en)
Inventor
James J Morrissey
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE185901T1 publication Critical patent/ATE185901T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92917364T 1991-04-10 1992-04-09 Quantitativer gerinnungstest für aktivierten faktor vii ATE185901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/683,682 US5472850A (en) 1991-04-10 1991-04-10 Quantitative clotting assay for activated factor VII

Publications (1)

Publication Number Publication Date
ATE185901T1 true ATE185901T1 (de) 1999-11-15

Family

ID=24745031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92917364T ATE185901T1 (de) 1991-04-10 1992-04-09 Quantitativer gerinnungstest für aktivierten faktor vii

Country Status (10)

Country Link
US (3) US5472850A (de)
EP (1) EP0641443B1 (de)
JP (1) JP3047120B2 (de)
KR (1) KR940700679A (de)
AT (1) ATE185901T1 (de)
AU (1) AU663713B2 (de)
CA (1) CA2108282C (de)
DE (2) DE641443T1 (de)
ES (1) ES2072243T3 (de)
WO (1) WO1992018870A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
AU663343B2 (en) * 1991-10-04 1995-10-05 Dade Behring Inc. Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1994007515A1 (en) * 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
DK0690991T4 (da) * 1993-01-29 2004-02-16 T A C Thrombosis And Coagulati Ny antikoagulant-cofaktor-aktivitet
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism
US5839443A (en) 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
IL130908A0 (en) 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment
EP0975975A1 (de) * 1997-04-09 2000-02-02 Blutspendedienst der DRK-Landesverbände Nordrhein und Westfalen-Lippe GmbH Verfahren zur bestimmung von aktivierten blutgerinnungsfaktoren in plasma und plasmaderivaten
DE19714559C1 (de) * 1997-04-09 1998-08-06 Blutspendedienst Der Drk Lande Verfahren zur Bestimmung von aktivierten Blutgerinnungsfaktoren in Plasma und Plasmaderivaten
DE69832628T2 (de) * 1997-04-23 2006-09-07 Instrumentation Laboratory S.P.A. Rekombinant-kaninchengewebefaktor basiertes prothrombinzeitreagenz
DE19720853A1 (de) * 1997-05-17 1998-11-19 Dade Behring Marburg Gmbh Erhöhung der FVII Empfindlichkeit eines Thromboplastinreagenzes
US6245573B1 (en) 1998-02-12 2001-06-12 University Of Medicine And Dentistry Of New Jersey Rapid assessment of the coagulant activity of blood
AU748847B2 (en) 1998-02-27 2002-06-13 Pamgene B.V. Method for the non-specific amplification of nucleic acid
WO1999049803A1 (en) * 1998-04-01 1999-10-07 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
WO1999064622A1 (en) 1998-06-08 1999-12-16 University Of Vermont And State Agriculture College Inhibition of coagulation in blood and blood products
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
GB2358862B (en) * 1999-12-21 2004-07-21 Fermentron Ltd Processes for Extracting Carotenoids from Biomass Carotenoid Sources
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6743596B1 (en) * 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US7110118B2 (en) * 2000-12-19 2006-09-19 Trustees Of Boston University Spectral imaging for vertical sectioning
DE10064689B4 (de) * 2000-12-22 2004-08-05 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Verfahren zur Bestimmung der Blutzellhämostase
US6596543B2 (en) 2001-03-22 2003-07-22 Dade Behring Inc. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
EP1260817A3 (de) * 2001-05-08 2002-12-18 Warner-Lambert Company Methode zur Direktbestimmung von Koagulationsfaktor VIIa in Plasma
ES2407355T3 (es) * 2001-07-03 2013-06-12 Oklahoma Medical Research Foundation Ensayo para medir los complejos de factor VIIa-antitrombina
EP1432447A2 (de) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Kombinierte zusammensetzung und methoden zur behandlung der koagulation tumorgefäss
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
AU2003290663A1 (en) * 2002-11-13 2004-06-03 Haematologic Technologies, Inc. Assay for tissue factor and factor viia
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
WO2005016365A2 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
RU2270020C2 (ru) * 2004-04-20 2006-02-20 Государственное учреждение Кировский научно-исследовательский институт гематологии и переливания крови (ГУ Книги ПК) Способ получения контрольной плазмы с нормальным уровнем протромбинового комплекса
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
US20080260858A1 (en) * 2005-02-16 2008-10-23 The Board Of Trustees Of The University Of Illnois Universal Procoagulant
DE602006021290D1 (de) * 2005-03-04 2011-05-26 Univ Illinois Modulator von coagulationskaskaden und fibrinolytischen kaskaden
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
US8574849B2 (en) * 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
US8821861B2 (en) * 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
DE102009048199A1 (de) * 2009-10-05 2011-04-21 Siemens Healthcare Diagnostics Products Gmbh Verfahren zur Bestimmung von Faktor XIII mit Hilfe von Referenzmaterial auf Plasmabasis
JP5851410B2 (ja) 2009-10-30 2016-02-03 シーエヌジェイ ホールディングス、インク． 組換えビタミンｋ依存性タンパク質の生成法
WO2014019644A1 (en) * 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
US11480559B2 (en) * 2016-01-07 2022-10-25 Fujimori Kogyo Co., Ltd. Blood collection tube, reagent, and method for analyzing blood characteristics using same
JP6626761B2 (ja) * 2016-03-30 2019-12-25 シスメックス株式会社 プロトロンビン時間測定用試薬およびその製造方法
CN116660554B (zh) * 2023-06-05 2025-10-03 成都协和生物技术有限责任公司 一种pt检测试剂制备方法
CN119959555B (zh) * 2025-04-10 2025-07-18 成都蓉生药业有限责任公司 一种测定动物样本中rFVIIa浓度的检测试剂盒及其检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479938A (en) * 1981-06-25 1984-10-30 Baxter Travenol Laboratories, Inc. Therapeutic composition containing factor VIIa
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
EP0225160B1 (de) * 1985-11-26 1991-08-21 Novo Nordisk A/S Zubereitungen und Verfahren zur Behandlung von Blutungsstörungen
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
EP0321526A1 (de) * 1987-06-12 1989-06-28 Mount Sinai School Of Medicine Of The City University Of New York Klonierung und expression von humanem gewebefaktor
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Also Published As

Publication number Publication date
AU1872992A (en) 1992-11-17
US5472850A (en) 1995-12-05
ES2072243T3 (es) 2000-03-16
KR940700679A (en) 1994-02-23
DE69230183T2 (de) 2000-08-31
DE641443T1 (de) 1995-10-12
JPH06506601A (ja) 1994-07-28
WO1992018870A1 (en) 1992-10-29
DE69230183D1 (de) 1999-11-25
US5750358A (en) 1998-05-12
AU663713B2 (en) 1995-10-19
US5741658A (en) 1998-04-21
EP0641443B1 (de) 1999-10-20
JP3047120B2 (ja) 2000-05-29
EP0641443A1 (de) 1995-03-08
CA2108282C (en) 2003-09-09
ES2072243T1 (es) 1995-07-16
CA2108282A1 (en) 1992-10-11

Similar Documents

Publication Publication Date Title
ATE185901T1 (de) Quantitativer gerinnungstest für aktivierten faktor vii
DK0420332T3 (da) Fremgangsmåde til bestemmelse af det endogene trombinpotentiale af plasma og blod, samt et kit til anvendelse ved fremgangsmåden
PT984282E (pt) Particulas que tem incorporada uma composicao que compreende um composto quimioluminescente
DE3784589D1 (de) Verwendung von oxidase-enzymsystemen in chemilumineszierenden tests.
ES2063821T3 (es) Composicion de reactivo que comprende un dador de enzima.
DE69118516D1 (de) Kolorimetrische enzymatische analyse
CA2002208A1 (en) Extraction methods for preparing thromboplastin reagents
DK0690991T3 (da) Ny antikoagulant-cofaktor-aktivitet
DE69515901D1 (de) Szintillation-annäherungstest für n-acetylgalactosaminyl transferase-aktivität
CA2100567A1 (en) Protein S Chromogenic Assay
EP0121254A3 (en) Process for determining substrate or enzymatic activity
ATE107704T1 (de) Verfahren zur selbstdurchführung von enzymkinetik.
AU6385498A (en) Reagent for determining aptt
ATE208424T1 (de) Verwendung einer vanadin-bromperoxidase als ein signalgenerierendes enzym für chemilumineszierende systeme: testkits und analytische verfahren
CA2037434A1 (en) Functional assay for determining the protein s activity
ATE274702T1 (de) Verwendung derivatisierter reagenzien in chemilumineszenz- und elektrochemilumineszenz- nachweisverfahren
DE69928541D1 (de) Luziferase assay, zusammensetzungen und testsätze zu damit in zusammenhang stehenden verwendungen
MY104235A (en) High sensitivity detection of peroxidase activity.
ATE91024T1 (de) Festphasenimmunoassayverfahren.
ES2087892T3 (es) Utilizacion de la superoxido dismutasa en ensayos que implican una oxidasa.
DE69331708D1 (de) Von enzymen katalysierte chemilumineszente detektion von proteinen und nukleinsäuren durch verwendung von hydroxyaryl-cyclischen diacylhydrazid-zusammensetzungen
UA33566A (uk) Спосіб кількісного визначення ципрофлоксацину

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties